Inflammatory Breast Cancer - 25 Studies Found Recruiting : Case-Control Study of Inflammatory Breast Cancer in North Africa : Inflammatory Breast Cancer : 2008-11-18 Completed : Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer : Inflammatory Breast Cancer : 2011-05-25 : Biological: Bevacizumab During Completed : Establishing an Inflammatory Breast Cancer Registry : Inflammatory Breast Cancer : 2006-06-19 Completed : Pilot Study of Inflammatory Breast Cancer in Egypt and Tunisia : Inflammatory Breast Cancer : 2006-06-23 Completed : Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer : Inflammatory Breast Cancer (IBC) : 2016-08-09 : Drug: Ruxolitinib 15 or 20 mg, Completed : Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer : Inflammatory Breast Cancer : 2014-12-14 : Drug: Docetaxel Drug: Cyclophosphamide Completed : A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer : Inflammatory Breast Cancer Human Epidermal Growth Factor 2 Nega : 2015-12-02 : Drug: Eribulin administered IV Completed : Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy : Inflammatory Breast Carcinoma : 2013-06-25 : Drug: 89Zr-bevacizumab 89Zr-be Completed : A Study of Anti-PD-1 (Pembrolizumab) + Hormonal Therapy in HR-positive Localized IBC Patients With Non-pCR to Neoadjuvant Chemotherapy : Inflammatory Breast Cancer Malignant Neoplasm of Breast : 2016-11-21 : Drug: Pembrolizumab Pembrolizumab 200 mg administered on day 1 of each 3-week cycle as approximately 30 Not yet recruiting : Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer : HER2/Neu Negative Recurrent Inflammatory Breast Carcinoma : 2016-09-02 : Biological: Ipilimumab Given I Next >>>
